Moreover, in the ENCORE 301 study (NCT00676663) [26], entinostat was shown to restore sensitivity to hormonal therapy and to improve PFS and OS when given in combination with exemestane in patients with ER-positive advanced BC resistant to previous aromatase inhibitors. This evidence concerns the gene CYP19A1 and breast cancer.